ArticleIndian pediatrics2026
Outcomes of Childhood Acute Lymphoblastic Leukemia Treated with Modified BFM-2009 Protocol Using Measurable Residual Disease-Based Risk-Stratification: A Single-Center Study.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChemotherapeutic protocols developed in high-income countries do not produce comparable results in low- and lower-middle income countries (LMICs). This study analyzed the treatment outcomes of modified Berlin-Frankfurt-Munster (BFM)-2009 protocol in children with acute lymphoblastic leukemia (ALL) in a tertiary care referral center in Northern India.
methodsThis retrospective study evaluated the treatment outcomes of children with newly diagnosed ALL treated with the modified BFM-2009 protocol using a risk-stratified approach between July 2018 and Dec 2024 and followed-up till June 2025.
resultsOne hundred sixty six children with a median (q1, q3) age 51 (31, 78) months were followed-up over a median (range) duration of 36.5 (6-84) months. Patients were categorized as standard-risk (SR, 34%), intermediate-risk (IR, 36%) and high-risk (HR, 30%). Extra-medullary disease was seen in 1 child and T-cell lineage in 27 (16%). On day 8, 13 out of 160 children (8%) had prednisolone poor response (PPR). At end of induction-I, 159 out of 160 patients were in morphological remission (marrow blasts < 5%) and measurable residual disease (MRD) was positive in 23 out of 156 (14.7%). At the end of re-intensification phase (induction-II), MRD was positive in 5 children. Relapse and overall toxic deaths were seen in 16/166 (9.6%) and 8/162 (4.9%) children. Event-free survival (EFS) and overall survival (OS) at 36-month follow-up for SR, IR and HR were 95.7% and 96.5%, 83% and 85%, 76.9% and 79%, respectively. Children with PPR and IR/HR were associated with poor EFS.
conclusionAdapting, rather than, adopting a protocol in LMICs, improves outcomes for childhood ALL.
Indexed as
Identifiers
41678105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.